Here's What Key Metrics Tell Us About Biogen Inc. (BIIB) Q4 Earnings
https://www.zacks.com/stock/news/2225441/here-s-what-key-metrics-tell-us-about-biogen-inc-biib-q4-earnings?cid=CS-ZC-FT-fundamental_analysis|nfm-2225441
Feb 13, 2024 - The headline numbers for Biogen Inc. (BIIB) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
0
Sage Therapeutics (SAGE) Q4 Earnings & Revenues Beat Estimates
https://www.zacks.com/stock/news/2227123/sage-therapeutics-sage-q4-earnings-revenues-beat-estimates?cid=CS-ZC-FT-analyst_blog|earnings_article-2227123
Feb 15, 2024 - Sage Therapeutics' (SAGE) earnings and revenues surpass estimates in the fourth quarter of 2023. Focus on newly launched PPD drug, Zurzuvae. Stock rise.
0
Biotech Stock Roundup: BIIB, BMY's Q1 Earnings, INCY's Acquisition & Updates from VRTX
https://www.zacks.com/stock/news/2262685/biotech-stock-roundup-biib-bmy-s-q1-earnings-incy-s-acquisition-updates-from-vrtx?cid=CS-ZC-FT-analyst_blog|earnings_article-2262685
Apr 25, 2024 - Biogen (BIIB) and Bristol Myers (BMY) are in focus following Q1 earnings announcement.
0
Sage Therapeutics (SAGE) Q1 Earnings Miss, Sales Beat Estimates
https://www.zacks.com/stock/news/2263560/sage-therapeutics-sage-q1-earnings-miss-sales-beat-estimates?cid=CS-ZC-FT-analyst_blog|earnings_article-2263560
Apr 26, 2024 - Sage Therapeutics' (SAGE) first-quarter 2024 results are mixed as earnings miss estimates, but sales beat the mark. The newly-launched depression drug Zurzuvae drives the company's top line.
0